Menu Search
Equities

Novo Nordisk A/S

NVO:NYQ

Novo Nordisk A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)102.63
  • Today's Change-2.64 / -2.51%
  • Shares traded6.18m
  • 1 Year change-0.15%
  • Beta0.4155
Data delayed at least 15 minutes, as of Nov 21 2024 23:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform5
Hold2
Sell0
Strong Sell1

Share price forecast in DKK

The 9 analysts offering 12 month price targets for Novo Nordisk A/S (ADR) have a median target of 154.70, with a high estimate of 166.67 and a low estimate of 85.33. The median estimate represents a 46.95% increase from the last price of 105.27.
High58.3%166.67
Med47.0%154.70
Low-18.9%85.33

Dividends in DKK

In 2023, Novo Nordisk A/S reported a dividend of 6.95 DKK, which represents a 24.98% increase over last year. The 3 analysts covering the company expect dividends of 11.53 DKK for the upcoming fiscal year, an increase of 65.91%.
Div growth (TTM)24.98%
More ▼

Earnings history & estimates in DKK

On Nov 06, 2024, Novo Nordisk A/S (ADR) reported 3rd quarter 2024 earnings of 6.12 per share. This result was in line with the consensus of the 5 analysts following the company and exceeded last year's 3rd quarter results by 22.40%.
The next earnings announcement is expected on Feb 05, 2025.
Average growth rate+7.31%
Novo Nordisk A/S (ADR) reported annual 2023 earnings of 18.62 per share on Jan 31, 2024.
Average growth rate+23.83%
More ▼

Revenue history & estimates in DKK

Novo Nordisk A/S (ADR) had 3rd quarter 2024 revenues of 71.31bn. This missed the 71.75bn consensus estimate of the 5 analysts following the company. This was 33.62% above the prior year's 3rd quarter results.
Average growth rate+5.07%
Novo Nordisk A/S (ADR) had revenues for the full year 2023 of 232.26bn. This was 31.26% above the prior year's results.
Average growth rate+17.97%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.